JP2017533925A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533925A5 JP2017533925A5 JP2017525536A JP2017525536A JP2017533925A5 JP 2017533925 A5 JP2017533925 A5 JP 2017533925A5 JP 2017525536 A JP2017525536 A JP 2017525536A JP 2017525536 A JP2017525536 A JP 2017525536A JP 2017533925 A5 JP2017533925 A5 JP 2017533925A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- item
- pharmaceutically acceptable
- het
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- -1 methyl butoxy Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000004968 inflammatory condition Effects 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 201000009961 allergic asthma Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079027P | 2014-11-13 | 2014-11-13 | |
| US62/079,027 | 2014-11-13 | ||
| PCT/IB2015/058774 WO2016075661A1 (en) | 2014-11-13 | 2015-11-13 | Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017533925A JP2017533925A (ja) | 2017-11-16 |
| JP2017533925A5 true JP2017533925A5 (OSRAM) | 2018-12-20 |
Family
ID=54601865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525536A Ceased JP2017533925A (ja) | 2014-11-13 | 2015-11-13 | アレルギー性疾患又は他の炎症状態の治療に有用なアデニン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10584125B2 (OSRAM) |
| EP (1) | EP3218377B1 (OSRAM) |
| JP (1) | JP2017533925A (OSRAM) |
| CN (1) | CN107108628A (OSRAM) |
| BE (1) | BE1023340B1 (OSRAM) |
| BR (1) | BR112017009648A2 (OSRAM) |
| CA (1) | CA2967248A1 (OSRAM) |
| ES (1) | ES2917887T3 (OSRAM) |
| MX (1) | MX2017006302A (OSRAM) |
| WO (1) | WO2016075661A1 (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10584125B2 (en) * | 2014-11-13 | 2020-03-10 | Glaxosmithkline Biologicals Sa | Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions |
| US10646566B2 (en) | 2015-03-10 | 2020-05-12 | Glaxosmithkline Biologicals S.A. | Compositions and uses |
| JP6744622B2 (ja) * | 2016-06-16 | 2020-08-19 | 学校法人上智学院 | ピペリジン化合物の製造方法 |
| US10947214B2 (en) * | 2016-08-08 | 2021-03-16 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CA3091142C (en) | 2018-02-26 | 2023-04-11 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| EP4458975A3 (en) | 2019-09-30 | 2025-02-12 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN118165930B (zh) * | 2024-04-16 | 2024-10-01 | 颖奕干细胞生物科技(海南)有限公司 | 一种长效维持血液中pbmc细胞的方法 |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ263686A (en) | 1993-03-17 | 1997-09-22 | Minnesota Mining & Mfg | Medicinal aerosol with dispersing aid derived from a hydroxy acid, an amino acid and/or a mercapto acid |
| US5995834A (en) | 1996-12-24 | 1999-11-30 | At&T Wireless Services, Inc. | Method for controlling channel re-selection from a selected control channel to an alternative control channel |
| US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
| EP1065213A3 (en) | 1999-07-02 | 2003-11-05 | Japan Tobacco Inc. | HCV polymerase suitable for crystal structure analysis and method for using the enzyme |
| SK13752001A3 (sk) | 1999-12-27 | 2002-07-02 | Japan Tobacco, Inc. | Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
| HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| IL157940A0 (en) | 2001-03-19 | 2004-03-28 | Ono Pharmaceutical Co | Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP1497469A4 (en) | 2002-04-04 | 2005-06-08 | Achillion Pharmaceuticals Inc | TEST FOR ASSESSING THE ACTIVITY OF COMPOUNDS AGAINST HCV USING A NOVEL DETECTION SYSTEM IN THE HCV REPLICIC |
| DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
| WO2004037818A1 (en) | 2002-10-24 | 2004-05-06 | Glaxo Group Limited | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
| CN1744899A (zh) | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| AU2003300952A1 (en) | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Indane compounds as ccr5 antagonists |
| DE60322423D1 (de) | 2002-12-13 | 2008-09-04 | Smithkline Beecham Corp | Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten |
| ES2312856T3 (es) | 2002-12-13 | 2009-03-01 | Smithkline Beecham Corporation | Compuestos heterociclicos como antagonistas de ccr5. |
| ES2298627T3 (es) | 2002-12-13 | 2008-05-16 | Smithkline Beecham Corporation | Compuestos de ciclopropilo como antagonistas de ccr5. |
| ES2311755T3 (es) | 2002-12-13 | 2009-02-16 | Smithkline Beecham Corporation | Compuestos de ciclohexilo como antagonistas de ccrs. |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| CN102028994B (zh) | 2003-11-03 | 2013-04-24 | 葛兰素集团有限公司 | 流体分配装置 |
| IN2012DN04853A (OSRAM) | 2004-02-20 | 2015-09-25 | Boehringer Ingelheim Int | |
| EP1748991A1 (en) | 2004-04-28 | 2007-02-07 | Arrow Therapeutics Limited | Morpholinylanilinoquinazo- line derivatives for use as antiviral agents |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| CA2577525C (en) | 2004-08-18 | 2010-03-30 | Pfizer Inc. | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
| GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| KR20080019213A (ko) | 2005-05-09 | 2008-03-03 | 아칠리온 파르마세우티칼스 인코포레이티드 | 티아졸 화합물 및 그 사용방법 |
| EP1939199A4 (en) | 2005-09-22 | 2010-10-20 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
| TW200843779A (en) * | 2007-02-19 | 2008-11-16 | Smithkline Beecham Corp | Compounds |
| CN102176911B (zh) * | 2008-08-11 | 2014-12-10 | 葛兰素史密丝克莱恩有限责任公司 | 新的腺嘌呤衍生物 |
| KR20110042116A (ko) * | 2008-08-11 | 2011-04-22 | 글락소스미스클라인 엘엘씨 | 알레르기성, 염증성 및 감염성 질환의 치료에서 사용하기 위한 푸린 유도체 |
| UA103195C2 (uk) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| KR20110077004A (ko) | 2008-10-24 | 2011-07-06 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 지질화된 이미다조퀴놀린 유도체 |
| NZ593110A (en) * | 2008-12-09 | 2013-06-28 | Gilead Sciences Inc | pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS |
| EA023536B1 (ru) | 2009-08-07 | 2016-06-30 | Глаксосмитклайн Байолоджикалс Са | Производные оксоаденина, конъюгированные с фосфо- или фосфонолипидами |
| WO2011098451A1 (en) | 2010-02-10 | 2011-08-18 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| BR112012018904A2 (pt) * | 2010-02-10 | 2020-09-01 | Glaxosmithkline Llc | composto, adjuvante de vacina, composições imunogênica, de vacina e farmacêutica, e uso de um composto" |
| US10584125B2 (en) * | 2014-11-13 | 2020-03-10 | Glaxosmithkline Biologicals Sa | Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions |
-
2015
- 2015-11-13 US US15/526,345 patent/US10584125B2/en active Active
- 2015-11-13 ES ES15797460T patent/ES2917887T3/es active Active
- 2015-11-13 JP JP2017525536A patent/JP2017533925A/ja not_active Ceased
- 2015-11-13 BE BE2015/5741A patent/BE1023340B1/fr not_active IP Right Cessation
- 2015-11-13 WO PCT/IB2015/058774 patent/WO2016075661A1/en not_active Ceased
- 2015-11-13 CN CN201580071475.2A patent/CN107108628A/zh active Pending
- 2015-11-13 CA CA2967248A patent/CA2967248A1/en not_active Abandoned
- 2015-11-13 MX MX2017006302A patent/MX2017006302A/es unknown
- 2015-11-13 BR BR112017009648A patent/BR112017009648A2/pt not_active Application Discontinuation
- 2015-11-13 EP EP15797460.1A patent/EP3218377B1/en active Active
-
2020
- 2020-01-17 US US16/745,569 patent/US10919894B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533925A5 (OSRAM) | ||
| JP2018524390A5 (OSRAM) | ||
| JP2009507909A5 (OSRAM) | ||
| JP2014511892A5 (OSRAM) | ||
| JP2013510123A5 (OSRAM) | ||
| JP2015501833A5 (OSRAM) | ||
| JP2015511638A5 (OSRAM) | ||
| JP2016530259A5 (OSRAM) | ||
| RU2014115290A (ru) | Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов | |
| JP2013510120A5 (OSRAM) | ||
| JP2013542261A5 (OSRAM) | ||
| RU2015143843A (ru) | Ингибиторы гистондеацетилазы | |
| RU2012153164A (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательного пути | |
| EA201100113A1 (ru) | Производные пурина для применения в лечении аллергических, воспалительных и инфекционных заболеваний | |
| TW200616968A (en) | Compound having basic substituent and application thereof | |
| JP2016503797A5 (OSRAM) | ||
| RU2015146957A (ru) | Производные доластатина 10 и ауристатинов | |
| RU2013104401A (ru) | Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы | |
| JP2012513416A5 (OSRAM) | ||
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| UA114645C2 (uk) | Піролопіримідини як індуктори інтерферону людини | |
| RU2018113718A (ru) | Новые соединения | |
| JP2020500866A5 (OSRAM) | ||
| JP2017513824A5 (OSRAM) | ||
| RU2018106498A (ru) | Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека |